Communiqués Amgen Inc.

Actions

AMGN

US0311621009

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
429,88 ^USD	-0,59 %		-3,15 %	+31,34 %

31/08	Donald Trump prépare de nouveaux accords pour réduire le prix des médicaments
31/08	L'administration Trump s'apprête à annoncer des accords sur le prix des médicaments	RE

Communiqués

31/08	AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE	PR
28/08	AstraZeneca - Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	AQ
27/08	TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS	PR
04/08	Amgen: Q2 Earnings Snapshot	AQ
04/08	AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS	PR
30/07	AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND	PR
29/07	Amgen : POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE	PU
28/07	AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS	PR
27/07	Protecting Antibody Innovations Beyond Composition Claims	AQ
24/07	Amgen : Statement on FDA Data Submission for TAVNEOS® (avacopan)	PU
08/07	Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech	PU
22/06	Amgen : What a Landmark Real-World Study Reveals About Thyroid Eye Disease	PU
07/06	AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS	PR
04/06	AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	PR
04/06	Bob Bradway on AI: Reimagining the Future of Biotechnology	PU
03/06	AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026	PR
01/06	Amgen : EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER	PU
29/05	AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE	PR
20/05	Amgen : Approach to AI-Enabled Clinical Development	PU
19/05	AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH	PR
16/05	Amgen : Statement on TAVNEOS® (avacopan)	PU
15/05	Amgen : 2026 Annual Meeting of Stockholders Presentation Non GAAP Reconciliations	PU
12/05	Amgen : The Story of Maridebart Cafraglutide (MariTide)	PU
07/05	AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE	PR
06/05	Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery	PU